Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies, which are expected to move into clinical trials in the next several months, were both developed by Purdue University scientists in Indiana, led by Philip…
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, has granted $920,000 to a team of researchers at the University at Buffalo (UB) to develop a model that mimics human lung tissue. The researchers say their model should offer an accurate and rapid…
Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks of therapy, a small study found. …
Bridge Biotherapeutics and Boehringer Ingelheim ended a collaboration and license agreement to develop BBT-877, a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders. The companies entered into an agreement in July 2019 and, although no details were provided about its termination, the…
Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization of OncoArendi’s OATD-01, an investigational treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Lung diseases like IPF are characterized by increased activity of enzymes called…
Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study found. While…
A real-world analysis found that idiopathic pulmonary fibrosis (IPF) patients with preserved lung function benefitted from treatment with Ofev (nintedanib) and Esbriet (pirfenidone) over three years. Despite untreated patients entering this study…
Lung cancer contributes to a poor prognosis in patients with idiopathic pulmonary fibrosis (IPF), a new study indicates. The finding suggests that healthcare professionals should monitor the development and progression of cancer in patients with IPF, given its negative impact on prognosis. The study, “Prognostic impact of malignant…
FibroGen’s experimental antifibrotic therapy pamrevlumab may be more effective than Esbriet (pirfenidone) and Ofev (nintedanib) at slowing disease progression in people with idiopathic pulmonary fibrosis (IPF), according to a review study. Combined data from eight clinical trials showed that all three therapies significantly…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations and research programs to help people with rare diseases. “The RareLaunch program is…
Get regular updates to your inbox.
